Morningside Venture Capital
Qiming, Orbimed lead Series A for China's Epigenic
Qiming Venture Partners and OrbiMed Asia Partners have led a USD 32m Series A round for Chinese gene editing therapy start-up Epigenic Therapeutics.
Morningside joins round for China's Epigenic Therapeutics
Morningside Venture Capital has teamed up with Kingray Capital, Trinity Innovation Fund, TigerYeah Capital, and FountainBridge Capital to provide USD 20m in angel and pre-Series A funding for Epigenic Therapeutics, a China-based gene editing specialist.
Singapore biotech start-up closes $125m Series C
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has led a $125 million Series C round for Hummingbird Bioscience, a Singapore and US-based drug developer.
China open source software player raises $43m Series B
Zilliz, a Chinese open-source software developer specializing in unstructured data processing and analysis, has raised a $43 million Series B round led by Hillhouse Capital affiliate GL Ventures.
China biotech player Gracell raises $100m Series C
Wellington Management, OrbiMed and Morningside Ventures have led a $100 million Series C round for Gracell Biotechnologies, a China-based developer of cancer treatments.
Morningside Venture Capital rebrands as 5Y Capital
Morningside Venture Capital has formally separated from Morningside Group, which is controlled by the Chan family, founders of Hong Kong property developer Hang Lung Group, and rebranded as 5Y Capital.